Market Overview:
The global beta-lactam and beta-lactamase inhibitors market is expected to register a CAGR of 5.8% during the forecast period, 2018–2030. The market growth can be attributed to the increasing incidence of bacterial infections, rising demand for novel antibiotics, and growing awareness about antibiotic resistance. Based on type, the global beta-lactam and beta-lactamase inhibitors market is segmented into penicillin, cephalosporin, carbapenem, monobactam, and combination. The penicillin segment is expected to account for the largest share of the global market in 2018. This can be attributed to its high efficacy against a wide range of bacteria as well as its low cost. However, owing to increasing resistance against penicillins by bacteria strains such as MRSA (methicillin resistant Staphylococcus aureus) and VRSA (vancomycin resistant Staphylococcus aureus), manufacturers are focusing on developing novel drugs that are effective against these strains. The cephalosporin segment is projected to grow at the highest CAGR during the forecast period owing to its high efficacy against Gram-negative bacteria such as Escherichia coli (E coli) and Klebsiella pneumoniae (K pneumoniae). Based on application, the global beta-lactam.
Product Definition:
Beta-lactam antibiotics are a group of structurally related antibiotics that share a common beta-lactam nucleus. The most important member of this group is penicillin, which is effective against a wide range of Gram-positive bacteria. Beta-lactamase inhibitors are drugs that inhibit the activity of beta-lactamases, enzymes produced by many species of bacteria that destroy the beta lactam ring structure in β lactams, rendering them inactive. This class of drugs thus enhances the effectiveness of β lactams against bacterial infections caused by organisms that produce these enzymes.
Penicillin:
Penicillin is a group of antibiotics derived from Penicillium fungi. The drug was first isolated and characterized in 1928, by the Scottish physician and bacteriologist Alexander Fleming. Since that time, it has been one of the most important groups of antibiotics ever discovered; its importance being recognized worldwide during the past 30 years.
The global penicillin market size spans two product categories-penicillin G (gentamicin).
Cephalosporin:
Cephalosporin is a type of antibiotic. It's structure consists of a ring with two nitrogen and one oxygen atom.
The molecular weight of the antibiotic is about 300 Da.
Application Insights:
Oral was the largest application segment in 2017 and is expected to maintain its dominance over the forecast period. This can be attributed to factors such as increasing healthcare spending, growing geriatric population, and technological advancements that have led to a rise in demand for PPI drugs. The intravenous segment is anticipated to witness considerable growth during the forecast period owing to rising usage of IV antibiotics for treatment purposes.
The others segment includes skin infections, UTI & pelvic infections, ear infections etc., where beta-lactamase inhibitors are used due largely on their ability against other bacteria that cause similar symptoms as well as due their cost effectiveness when compared with other antibiotic options available in the market.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing incidence of infectious diseases, rising geriatric population, and high healthcare expenditure. Asia Pacific is anticipated to witness lucrative growth over the coming years owing to improving economic conditions and growing demand for antibiotics in this region. Moreover, new product launches are also expected to boost regional growth over the forecast period. For instance, Teva Pharmaceuticals USA announced about launching a new formulation of Augmentin (amoxicillin/clavulanate potassium) tablets for oral suspension in August 2016; these products are approved only for intravenous use at doses not suitable for adults taking them orally.
The key players operating in this industry include Pfizer Inc.; Merck & Co., Inc.; FMC Corporation; Abbott Laboratories; AbbVie Inc.
Growth Factors:
- Increasing incidence of bacterial infections: The increasing incidence of bacterial infections is a major growth driver for the beta-lactam and beta-lactamase inhibitors market. This is because the use of these drugs helps in the treatment of such infections.
- Rising demand for novel antibiotics: The rising demand for novel antibiotics is another key growth driver for this market. This is because the use of such drugs offers better efficacy and fewer side effects as compared to traditional antibiotics.
- Growing awareness about antibiotic resistance: There has been a growing awareness about antibiotic resistance in recent years, which has led to an increase in the demand for beta-lactam and beta-lactamase inhibitors products worldwide.
- Technological advancements: The technological advancements in drug discovery and development have helped to boost the growth prospects of this market considerably over the past few years. These advancements have resulted in new drug formulations being launched into this market, thereby offering greater choice to consumers as well as healthcare professionals alike . 5) Expanding product pipeline: The expanding product pipeline is another key factor that is expected to fuelgrowthinthismarketinthecomingyears
Scope Of The Report
Report Attributes
Report Details
Report Title
Beta-lactam and Beta-lactamase Inhibitors Market Research Report
By Type
Penicillin, Cephalosporin, Carbapenem, Monobactam, Combination
By Application
Oral, Intravenous, Others
By Companies
Abbott Laboratories, Allergan Plc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co. Inc., Mylan N.V., Novartis International AG (Sandoz), Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
126
Number of Tables & Figures
89
Customization Available
Yes, the report can be customized as per your need.
Global Beta-lactam and Beta-lactamase Inhibitors Market Report Segments:
The global Beta-lactam and Beta-lactamase Inhibitors market is segmented on the basis of:
Types
Penicillin, Cephalosporin, Carbapenem, Monobactam, Combination
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Oral, Intravenous, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott Laboratories
- Allergan Plc.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Merck & Co. Inc.
- Mylan N.V.
- Novartis International AG (Sandoz)
- Pfizer Inc.
- Sanofi
- Teva Pharmaceutical Industries Ltd
Highlights of The Beta-lactam and Beta-lactamase Inhibitors Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Penicillin
- Cephalosporin
- Carbapenem
- Monobactam
- Combination
- By Application:
- Oral
- Intravenous
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Beta-lactam and Beta-lactamase Inhibitors Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Beta-lactam and beta-lactamase inhibitors are medications that work to stop the growth of bacteria. These medications are often used to treat infections, such as pneumonia, urinary tract infections (UTIs), and skin infections.
Some of the major companies in the beta-lactam and beta-lactamase inhibitors market are Abbott Laboratories, Allergan Plc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co. Inc., Mylan N.V., Novartis International AG (Sandoz), Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd.
The beta-lactam and beta-lactamase inhibitors market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Beta-lactam and Beta-lactamase Inhibitors Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Beta-lactam and Beta-lactamase Inhibitors Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Beta-lactam and Beta-lactamase Inhibitors Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Beta-lactam and Beta-lactamase Inhibitors Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Beta-lactam and Beta-lactamase Inhibitors Market Size & Forecast, 2018-2028 4.5.1 Beta-lactam and Beta-lactamase Inhibitors Market Size and Y-o-Y Growth 4.5.2 Beta-lactam and Beta-lactamase Inhibitors Market Absolute $ Opportunity
Chapter 5 Global Beta-lactam and Beta-lactamase Inhibitors Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast by Type
5.2.1 Penicillin
5.2.2 Cephalosporin
5.2.3 Carbapenem
5.2.4 Monobactam
5.2.5 Combination
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Beta-lactam and Beta-lactamase Inhibitors Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast by Applications
6.2.1 Oral
6.2.2 Intravenous
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Beta-lactam and Beta-lactamase Inhibitors Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Beta-lactam and Beta-lactamase Inhibitors Analysis and Forecast
9.1 Introduction
9.2 North America Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast by Type
9.6.1 Penicillin
9.6.2 Cephalosporin
9.6.3 Carbapenem
9.6.4 Monobactam
9.6.5 Combination
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast by Applications
9.10.1 Oral
9.10.2 Intravenous
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Beta-lactam and Beta-lactamase Inhibitors Analysis and Forecast
10.1 Introduction
10.2 Europe Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast by Type
10.6.1 Penicillin
10.6.2 Cephalosporin
10.6.3 Carbapenem
10.6.4 Monobactam
10.6.5 Combination
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast by Applications
10.10.1 Oral
10.10.2 Intravenous
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast by Type
11.6.1 Penicillin
11.6.2 Cephalosporin
11.6.3 Carbapenem
11.6.4 Monobactam
11.6.5 Combination
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast by Applications
11.10.1 Oral
11.10.2 Intravenous
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Beta-lactam and Beta-lactamase Inhibitors Analysis and Forecast
12.1 Introduction
12.2 Latin America Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast by Type
12.6.1 Penicillin
12.6.2 Cephalosporin
12.6.3 Carbapenem
12.6.4 Monobactam
12.6.5 Combination
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast by Applications
12.10.1 Oral
12.10.2 Intravenous
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Beta-lactam and Beta-lactamase Inhibitors Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast by Type
13.6.1 Penicillin
13.6.2 Cephalosporin
13.6.3 Carbapenem
13.6.4 Monobactam
13.6.5 Combination
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast by Applications
13.10.1 Oral
13.10.2 Intravenous
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Beta-lactam and Beta-lactamase Inhibitors Market: Competitive Dashboard
14.2 Global Beta-lactam and Beta-lactamase Inhibitors Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abbott Laboratories
14.3.2 Allergan Plc.
14.3.3 F. Hoffmann-La Roche Ltd.
14.3.4 GlaxoSmithKline plc
14.3.5 Merck & Co. Inc.
14.3.6 Mylan N.V.
14.3.7 Novartis International AG (Sandoz)
14.3.8 Pfizer Inc.
14.3.9 Sanofi
14.3.10 Teva Pharmaceutical Industries Ltd